US Unemployment Looms As A Threat To Pharma, But More Impact In 2021
Sweeping job losses in the US have left people uninsured or transitioning from private insurance to Medicaid, which will impact how drugs are reimbursed. Changing payer mix will have an effect on company revenues.
You may also be interested in...
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
Changing payer mix in diabetes due to the impacts of COVID-19 may be a central focus of Lilly's second quarter earnings call.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.